The politics of group B and the WIPO Broadcasting treaty

While some of the news reports have focused on north/south disputes over limitations and exceptions to rights in the WIPO Broadcasting treaty, there is a also a growing divide between North America (US and Canada) on the one hand, and Europe and Japan, on the other, over the nature of the rights in the treaty. The EU position (followed by Japan), which is being pushed by the very non-neutral Finish chair, is for Rome+ rights, to reward investment, not creativity. Continue Reading

Uncategorized

“a tough but commendable decision”

They go into session today at 10am to discuss how to report the week’s events to the WIPO General Assembly, so officially, nothing is decided yet, but it appears as though WIPO will not be approving a diplomatic conference. Jukka Liedes, who has apparently chaired the WIPO copyright committee for all but two days over a twenty year period, may try to find a way to keep this alive, but many delegates are determined to move on to something else. Continue Reading

Uncategorized

Rechazo al Tratado de Radiodifusión de la OMPI – Declaración conjunta de organizaciones no gubernamentales

Invitamos a los delegados de la OMPI a que rechacen la propuesta de Tratado de Radiodifusión en la OMPI.

Después de más que 9 años de discusiones, los esfuerzos para buscar una formulación del tratado que se ocupe de la piratería de las señales de radiodifusión, pero que no dañe a los titulares de derechos de autor y a los usuarios legítimos de emisiones, han fracasado.

Continue Reading

Uncategorized

Thailand’s Compulsory Licensing Controversy

Between November 2006 and January 2007, Thailand issued compulsory licenses for two AIDS drugs (efavirnz and the combination of lopinavir+ritonavir) and one antihypertension drug (clopidegrel).  The pharmaceutical industry has vehemently objected to these compulsory licenses, and has sought the US… Continue Reading

OECD high forum, where are the NGO voices?

The OECD High Level Forum to be held in the Netherlands on June 20 and 21, proposes to discuss new policy strategies to stimulate innovation for and access to medicines for neglected diseases. The meeting has on its face very laudable goals. But while NGOs have been invited to the HLF, they have not been given sufficient opportunity to contribute to the discussion Only one NGO has been invited to speak. By contrast other actors from academia and industry have been given multiple opportunities to present their views.

Continue Reading

Uncategorized